Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00992290 · ClinicalTrials.gov registry record · Phase 1
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00992290 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 37 participants.
The verdict
NCT00992290, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This research proposes to find whether the probiotic lactobacillus GG is safe and well tolerated in patients with minimal hepatic encephalopathy. We also want to get insight into the mechanisms of action of LGG.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Lactobacillus GG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00992290
The ClinicalTrials.gov registry entry for NCT00992290 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00992290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00992290 about?
NCT00992290 is a clinical study titled "Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy". This research proposes to find whether the probiotic lactobacillus GG is safe and well tolerated in patients with minimal hepatic encephalopathy. We also want to get insight into the mechanisms of action of LGG.
What is the current status of trial NCT00992290?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2009-10. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00992290?
The interventions under investigation include: Placebo (BIOLOGICAL), Lactobacillus GG (BIOLOGICAL).
Who is sponsoring clinical trial NCT00992290?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.